Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients

NCT06308159 is registered in ClinicalTrials.gov with Lantu Biopharma as lead sponsor.

NCT NCT06308159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06308159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients
Lead sponsor
Lantu Biopharma
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 11, 2024
Completion date
August 1, 2027
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia